CLINICAL TRIALS PROFILE FOR HYDROCHLOROTHIAZIDE; VALSARTAN
✉ Email this page to a colleague
All Clinical Trials for hydrochlorothiazide; valsartan
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00168779 ↗ | Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension | Completed | Boehringer Ingelheim | Phase 4 | 2005-09-01 | The primary objective of this study is to compare the effectiveness of telmisartan 80 mg / hydrochlorothiazide 25 mg [Micardis HCT] to valsartan 160 mg / hydrochlorothiazide 25 mg [Diovan HCT] and placebo in the treatment of Stage 1 and Stage 2 hypertension. |
| NCT00170937 ↗ | A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome | Completed | Novartis | Phase 4 | 2004-11-01 | The metabolic syndrome is a classification for patients with a constellation of risk factors which may include abdominal obesity, hypertension, elevated blood lipids and sugar. Three or more of these factors together constitute the metabolic syndrome and place these patients at a greater risk for the development of diabetes and cardiovascular diseases. The purpose of this study is to determine whether two common drugs to lower blood pressure, whether used separately or in combination, have different effects on blood sugar levels in patients diagnosed with the metabolic syndrome. |
| NCT00170989 ↗ | Valsartan/Hydrochlorothiazide Combination in Hypertensive Patients Not Controlled With Valsartan Alone | Completed | Novartis | Phase 3 | 2004-09-01 | This study will test the effectiveness and safety of a combination treatment in patients whose blood pressure is not controlled with a single medication. |
| NCT00171015 ↗ | VALORY Study of Valsartan/Hydrochlorizide for Patients Who do Not Respond Adequately to Olmesartan Medoxomil | Completed | Novartis | Phase 3 | 2004-12-01 | To evaluate the efficacy of valsartan 160 mg/HCTZ 25 mg in patients not adequately responding to monotherapy with olmesartan medoxomil 40 mg or combination therapy with olmesartan medoxomil 20 mg plus HCTZ 12.5 mg by testing the hypothesis that valsartan 160 mg/HCTZ 25 mg significantly reduces the trough mean sitting diastolic blood pressure (MSDBP) after a 4-week treatment in the nonresponder population. |
| NCT00171054 ↗ | Efficacy and Safety of Valsartan Versus Amlodipine in Postmenopausal Women With Hypertension | Completed | Novartis | Phase 4 | 2003-09-01 | The purpose of this study is compare treatment with valsartan with the possible addition of a diuretic, hydrochlorothiazide, on high blood pressure with the drug amlodipine with the possible addition of a diuretic, hydrochlorothiazide. In particular, the effect of treatment on the stiffness of the blood vessels will be studied. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for hydrochlorothiazide; valsartan
Condition Name
Clinical Trial Locations for hydrochlorothiazide; valsartan
Trials by Country
Clinical Trial Progress for hydrochlorothiazide; valsartan
Clinical Trial Phase
Clinical Trial Sponsors for hydrochlorothiazide; valsartan
Sponsor Name
